Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Twinrix in Cystic Fibrosis and Latent Tuberculosis
NCT02605538Withdrawn
- Sponsor
- Karolinska University Hospital
- Start
- Sep 2015
- Primary completion
- Dec 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of hepatitis b vaccine recombinant in hepatitis A (HAV) and hepatitis B (HBV) (2 arms), sponsored by Karolinska University Hospital. Primary endpoint: Positive antibody response to vaccination with Twinrix(TM) at 6 months. Planned start Sep 2015; status: withdrawn.
02
Drugs
hepatitis b vaccine recombinant
03
Conditions
hepatitis A (HAV)hepatitis B (HBV)
Beyond the preview
Go deeper on NCT02605538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02605538.